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Abstract
Most atrial fibrilation (AF)  patients  need anticoagulation
management to reduce the risk  of thromboembolic events and
stroke. Curently, two major drug therapies are available: warfarin
and  direct  oral anticoagulant (DOAC). This study examined the
spatial costs of these therapies and derived the least-cost market
areas for both therapies in the study area. The concepts of spatial
costs and the principles of forming market areas were used as the-
oretical starting  points, and the  patients’ travel, time-loss, and
medication cost parameters combined with geographical informa-
tion systems methods were incorporated into the geospatial model.
Results showed that for AF patients who live near the international
normalized ratio (INR)  monitoring sample colection  point and
have less than 15 annual INR monitoring visits, warfarin therapy
resulted in the lowest cost regardless of patient’s travel mode and
their assumed working or retirement status. If the AF patient needs
more frequent INR monitoring visits or lives farther from the near-
est sample colection  point,  DOAC  would  be the least costly
option. The modeled results reveal the variety and importance of
patients’ cost of time loss and travel costs when a physician selects
the appropriate anticoagulation therapy.
Introduction
Curently in Europe, atrial fibrilation (AF) afects 9 milion
people, and its increasing  prevalence raises the expenditures for
the  health care sector (Krijthe et  al.,  2013;  Zoni-Berisso et  al.,
2014). In addition to societal costs,  patients incur  notable time
costs and direct monetary travel costs for regular folow-up visits
(Jowet et al., 2008; Hwang et al., 2011). 
AF is the  most common form  of cardiac arhythmia, and its
prevalence increases  with age.  The  prevalence is  1.9%-2.9% in
Western countries, and the average age  of  AF  patients fals
between 75 and 84 (Zoni-Berisso et al., 2014). AF is associated
with a risk  of thromboembolic events and stroke (Amin,  2013;
Verhoef et al., 2014). Oral anticoagulation therapy is used for the
prevention  of a stroke and systemic embolism for  patients  who
have a high risk of complications (Halinen et al., 2014). Finnish
treatment guidelines recommend the use of anticoagulation thera-
py when a score between 1 and 2, based on CHA2DS2-VASc risk
estimation, is reached (Hammersley and Signy, 2017; The Finnish
Medical Society Duodecim, 2018).
Warfarin is a popular and inexpensive drug for anticoagulation
therapy and used worldwide for decades. However, the drug has
many adverse food interactions, which afects its pharmacokinet-
ics (Ansel et al., 2008). Frequent monitoring of the international
normalized ratio (INR) and drug dose adjustment are part of war-
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farin therapy to achieve the desired treatment targets (Halinen et
al.,  2014). INR  monitoring incurs costs,  both for the  health care
sector and the patients, and it raises the total cost of therapy for AF
patients using this drug (Pary et al., 2001; Schulman et al., 2010).
The Finnish Curent Care Guidelines for AF recommend that the
INR should  be  monitored  once a  month,  but the  monitoring fre-
quency can  be  higher  when the INR is  outside the therapeutic
range (The Finnish Medical Society Duodecim, 2018).
Direct  oral anticoagulants (DOACs)  became available as an
alternative to warfarin during the past decade. Clinical trials have
shown that the eficacy of DOACs is similar to warfarin (Connoly
et  al.,  2009;  Granger et  al.,  2011;  Patel et  al.,  2011),  while the
advantage is that these  drugs  prevent thromboembolic complica-
tions without regular monitoring (Silingardi, 2013). DOACs have
significantly less adverse interaction with food and drugs than war-
farin,  which alows fixed  dosing (Testa et  al.,  2012).  However,
DOAC drugs are more expensive than warfarin, and chronic kid-
ney disease and a mechanical heart valve are contraindications for
the use of DOACs (Hinojar et al., 2015). 
In Finland, DOACs are partialy reimbursable for non-valvular
AF  patients  whose  CHA2DS2-VASc score is  ≥1 (The  Finnish
Medical  Society  Duodecim,  2018).  After reimbursement  by the
Social Insurance Institution  of  Finland, the  daily  drug cost  of
DOACs is curently  between  0.93-1.01  €,  depending  on  which
specific DOAC drug is prescribed, while the coresponding cost of
warfarin is 0.07 € per day. The slow spread of DOACs may result
from the relatively  high  drug cost for the  patient.  However, fre-
quent journeys to a sample colection point increase his or her cost
for warfarin therapy. These additional costs narow the cost difer-
ence between warfarin and DOAC therapies, and hence the price
of warfarin is only a smal part of the total cost of warfarin therapy
(Schulman et al., 2010).
Previous assessments of this cost diference have mostly been
assessed from a  health care sector  perspective  based  on  quality-
adjusted life-years (Coyle et  al.,  2013;  Verhoef et  al.,  2014).
However, Marcolino et al.(2016) investigated the costs using cost-
minimization analysis from a societal  perspective including the
efect of patient travel costs and the cost of time lost in warfarin
therapy, finding that DOAC therapy in fact incured a lower cost,
at least for some patients.
The cost diference between warfarin therapy and DOAC ther-
apy  has  decreased.  However, earlier studies  have excluded the
least-cost optimisation for a patient between these two therapies,
including the cost of travel and time lost in health care districts. To
fil this research  gap,  our study aimed to  develop a  geospatial
model that can be used to determine the optimal alocation of both
therapies. We used the North Karelia health care district in Finland
as study area.
Materials and Methods
Study area and population
The study area consisted  of  14  municipalities (13 in  North
Karelia and one, Heinävesi, in Southern Savonia) with a total pop-
ulation  of  166,000 at the end  of  2017 (Statistics  Finland,  2017).
The population density is low (9.3 per km2), which is a chalenge
for the delivery of cost-eficient health care service, especialy in
smal centres and rural areas.
Blood samples for INR monitoring can be taken in 25 sample
colection points at health care centre premises. These sample col-
lection points are located mainly in municipality centres. The dis-
tance to the closest sample colection point is short for most of the
population but relatively long (sometimes over 60 km) for a patient
living in an outlying district.
Study design
We investigated the spatial costs  of  warfarin therapy and
DOAC therapy from the  AF  patients’ least-cost  perspective and
derived the market areas for both therapies. The least-cost optimi-
sation was done by measuring the patients’ travel, time-loss, and
medication costs as annual expenditures. The optimisation of the
least-cost anticoagulation therapy was implemented by applying a
theoretical  background  of industrial location formulated  by  Tord
Palander (Smith, 1981). We modified the principles of Palander’s
market area theory to suit our research task and geospatial model
(Figure 1). 
The total cost of warfarin therapy (TCwvi) consists of the cost
of the drug (Pw), the fixed costs of a monitoring visit (FCv) and the
extent of a travel cost per visit. Hence, the cost of warfarin therapy
is the lowest for patients who live near a sample colection point
and have a low number of annual INR monitoring visits. The total
cost  of  DOAC therapy (TCDOAC) is  both spatialy and annualy
fixed. Thus, we compared a variable cost of warfarin therapy with
this constant cost of DOAC therapy by creating the diferent INR
monitoring visit scenarios having a variable total cost (TCwvi) when
warfarin is  used (Figure  1).  The  maximum  TCwviconsists  of the
warfarin  price, INR  monitoring and the  maximum cost-eficient
travel cost (Pw+ FCv+ MaxCv); it is used to determine the spatial
joint isocostlines of both therapies. These isocost lines were cal-
culated separately for  diferent INR  monitoring frequencies  by
travel  mode and  working/retirement status, and the  market areas
were determined for both therapies by applying these lines in spa-
tial analyses.
Figure 1 shows the theoretical gradients of the total cost when
a patient on warfarin therapy has, as an example, one or two annual
INR monitoring visits. The steepness of a gradient depends on the
travel cost function of the travel mode and the number of annual
INR  monitoring  visits.  The  boundaries  of  market areas (Areaw,
AreaDOAC) were determined using the intercept of the gradient and
the total cost of DOAC therapy. The distance in the intercept, the
cut-of  distance, is the  maximum cost-eficient travel  distance
from the sample colection point to the cut-of isocost line in war-
farin therapy. 
Based on this framework, we constructed a geospatial model
using ArcGIS  Pro (ESRI,  Redlands,  CA,  USA) and  Python soft-
ware (htps:/www.python.org/psf/). The flowchart of the model is
presented in Figure 2. The model has two main sections: input data
and spatial analyses. First, constrained by the fixed DOAC medi-
cation cost, the model calculates the maximum cost-eficient travel
cost for diferent INR monitoring visits scenarios in warfarin ther-
apy, separately for working persons and retirees by travel modes.
This information is used as input data in geospatial derivation of
the boundaries of the market areas. Lastly, these calculated values
are  used in spatial analyses  one  by  one, and the  market areas  of
both therapies are derived for the diferent INR monitoring visits
scenarios by travel mode.
Assessment of cost parameters
The coeficients of the geospatial model consist of parameters
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depicting the cost of time loss, the costs of travel, and drug costs
(Figure 2). The cost functions and parameters were derived from
the data of the study area, but the model can be recalibrated with
distinct cost  parameters, and it can  be applied to  diferent  geo-
graphical areas. The input parameters of the model are shown in
Table 1.
The INR monitoring visit encompasses various cost elements
in addition to the transport cost. The time costs of warfarin therapy
consist  of the travel time to a sample colection  point, the time
spent there and the time used for dose adjustment at home (Jowet
et al., 2008). The time lost for the patients was converted to a mon-
etary cost by multiplying by the hourly value of time (VOT), cal-
culated  using the average  hourly income in the study area
(Statistics Finland, 2019). In the model, travel time was calculated
door-to-door (Salonen and Toivonen, 2013; Tenkanen et al., 2016)
and separately for  diferent travel  modes. Thus, the  whole round
trip between a starting point and the sample colection point was
covered by the time cost calculation (Table 1).
Earlier studies (Johannesson et al., 1991; Jowet et al., 2008;
Leminen et al., 2018) used a coeficient to value the lost working
and leisure time. In our study, the value coeficient of a patient’s
lost time (TL) had two diferent values. The TL for a working per-
son was set as equal to the average hourly income in the study area,
while a retiree’s  TL  was  valued as  35%  of the average  hourly
income. The division between subgroups was based on the curent
lowest retirement pension age (64 years of age). 
Travel cost functions and parameters were set by travel mode.
The direct travel costs of private car, taxi and bus were based on
the curent operating expenses and charges in the study area (Table
1). For taxi, the maximum direct monetary cost for a one-way trip
was set at 25 € because the Social Insurance Institution of Finland
reimburses a  patient’s  health care related travel costs  when the
one-way cost exceeds  25  € and traveling complies the criteria
(Social Insurance Institution  of  Finland,  2019).  Additionaly, an
upper limit  of  300  €  was considered for the annual travel cost
reimbursement. Bus fares were set based on the average cost of a
single ticket in the Joensuu region, as it is the  only subregion
where public transport is available in the study region. 
The drug costs were retrieved from the database of Association
of Finnish Pharmacies (Association of Finnish Pharmacies, 2018).
Four  diferent  DOAC  drugs (rivaroxaban, edoxaban,  dabigatran
and apixaban) were placed into two classes by the annual out-of-
pocket cost for  patients.  The  DOACs  prices  were  based  on the
lower special rate of reimbursement (65%), and the price of war-
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Figure 1. Derivation of boundaries between the market areas of warfarin therapy and direct oral anticoagulant (DOAC) therapy. Thesize of market areas is influenced by drug prices, the fixed costs of a monitoring visit, the number of sample colection point visits, andtravel cost in warfarin therapy. Cut-of distance is the distance between the isocost line and the sample colection point. P, price of med-icine; TC, total costs of therapy; MaxC, maximum travel cost; FC, fixed cost per visit; Cut-ofv1, cut-of distance with 1 visit; AreaDOACi,area for DOAC if patient has ‘i’ visit in warfarin therapy; w, warfarin; v1, one visit; v2, two visits.
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farin on the basic rate of reimbursement (40%). 
By  using  patient register  data from the same region,
researchers  have shown that the average annual INR  monitoring
frequency is 19.1 (standard deviation=13.7) in the Joensuu region
(Halinen et  al.,2014).  Based  on these findings,  we scaled the
annual INR  monitoring frequency from  6 to  30 to represent the
variation in the annual INR monitoring frequency in the model.
Equations to solve the maximum cost-eficient travel
cost in warfarin therapy
The maximum travel cost by INR monitoring visits (MaxCvi)
for  warfarin therapy  had to  be calculated  before the  geospatial
derivation of the boundaries of the market areas because the mar-
ket areas for the therapies are defined based on their isocost line
values. The annual cost of DOAC therapy was used as the baseline
and the starting  point  when the isocost lining  was implemented
between warfarin and DOAC therapy (Figure 1). 
We calculated the maximum travel cost in warfarin therapy for
four travel modes because patients use diverse travel modes when
they travel to a sample colection point (Figure 2). These costs vary
between travel modes and, according to Rodrigue et al. (2009), the
monetary cost is often the most important criterion for choosing a
travel  mode.  Folowing this,  we  utilised a  modified  door-to-door
approach (Salonen and Toivonen, 2013) for our geospatial model
for the four diferent travel modes, applying the study by Ford et
al. (2015).
In our study area, the main modes of travel are by private car
(CCAR), taxi (CTAXI), walking (CWALK), and public transport (CBUS).
The maximum travel cost per INR monitoring visit was calculated
separately for the diferent travel modes by the age groups and by
the annual INR monitoring frequencies. Because we observed that
the travel costs are linearly dependent on distance and TL, formu-
las for diferent travel modes were set using linear Eqs. 1a-1d:
where  CDOAC is the annual cost  of  DOAC after reimbursement;
CWAR the annual cost of warfarin after reimbursement; FREQ the
annual INR monitoring frequency, Tpthe parking time; Ttthe taxi
service time; Tmthe time spent in INR monitoring; Tdthe time esti-
mate for  dose adjustment in  warfarin therapy;  VOT the average
hourly gross wage of the health care district; TL the value coefi-
cient of lost time; Tbw1the average waiting time at a bus stop; Tbw2
the walking time to a bus stop; Ftthe fare paid for the taxi journey;
and Fbthe fare paid for the bus journey. The detailed coeficient
values can be seen in Table 1.
Al fixed costs of warfarin therapy were added to the Eqs. 1a-
1d, including the fixed costs during INR monitoring visits travels.
The  door-to-door approach  was simplified  by assuming fixed
walking times to connecting points and fixed waiting and service
times (Table 1). The Eqs. 1a-1d outputs reveal the maximum mon-
etary cost, which a patient can spend for traveling when the annual
costs of both therapies are set equal and the frequency and the costs
of INR monitoring are considered.
Preparation of digital road network and travel imped-
ances
The road  network and the locations  of the sample colection
points were used in the geospatial travel modeling (Figure 2). We
used the Digiroaddatabase from the  Finnish  Transport  Agency
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Table 1. Parameters used in the geospatial model.
Parameter                                        Description                                Value used in analysis
VOT                                          Based on average hourly income of North Karelia                                10.30 /h
Value coeficient of a patient’s TL            Working time valued as 100% of VOT, and leisure time of                         Working person: 1
                                                       a retiree valued as 35% of VOT                                             
Tm                                     Time spent in the international normalized ratio monitoring visit                           20 min
Td                                       Time spent for dose adjustment of warfarin after monitoring                            10 min
Tp                                                   Time spent for private car parking                                         5 min
Tt                                                          Service time of taxi                                                5 min
Tbw1                                                     Waiting time at a bus stop                                             7 min
Tbw2                                                     Walking time to a bus stop                                             5 min
VOCc                                               Vehicle operating cost for private car                                      0.45 /km
VOCt                                                         Charge for taxi                                                1.59 /km
Ft                                                          Initial charge of taxi                                               5.90 
Fb                                                    Fare paid for the journey by bus                                          3.80 
Sb                                                         Average speed of bus                                              30 km/h
Sw                                                       Average speed of walking                                            3.5 km/h
Cwar                                             Annual cost of warfarin after reimbursement                                   25.50 
CDOAC                                    Annual cost of direct oral anticoagulant after reimbursement              Dabigatran and apixaban = 369.30                                                                                                                Rivaroxaban and edoxaban = 338.30 
FREQ                                             Frequency of monitoring visits per year                                      6 to 30
VOT, value of time; TL, lost time; Tm, time spent in international normalized ratio (INR) monitoring; Td, time estimate for dose adjustment in warfarin therapy; Tp, parking time; Tt, taxi service time; Tbw1, average waiting
time at a bus stop; Tbw2, walking time to a bus stop; VOCc, vehicle operating cost for private car; VOCt, charge for taxi;, fare paid for the taxi journey; Fb, fare paid for the bus journey; Sb, bus average speed; Sw,patient’s
average walking speed; Cwar, annual cost of warfarin after reimbursement; CDOAC, annual cost of direct oral anticoagulant after reimbursement; FREQ, annual INR monitoring frequency.
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Figure 2. Flowchart of the geospatial model to the derivation of the market areas of warfarin therapy and direct oral anticoagulant ther-apy in a health care district. INR, international normalized ratio; DOAC, direct oral anticoagulant.
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modifying it to fulfil the demands of the model. For example, traf-
fic impediments (e.g., trafic lights and intersection delays) were
added to the network.
The model utilised temporal and spatial atributes of road seg-
ments in the analyses. We applied travel time and distance in the
equations to calculate the total travel cost of road segments by trav-
el modes. Eqs. 2a-2d express the travel costs by private car (CCAR),
taxi (CTAXI),  walking (CWALK), and  public transport (CBUS) in the
road network:
where VOC is the  vehicle cost  per  km; VOT the average  hourly
gross wage in the health care district; TL the value coeficient of
lost time; Swthe patient’s average walking speed; Sbthe bus aver-
age speed; len_DR_segment the length  of the road segment in
question; and time_DR_segment the travel time for this road seg-
ment by car. 
Determining the minimum costs of therapies for a patient
The least-cost  market areas  of therapies for  patients  were
derived by applying the two aspects of spatial accessibility in the
geospatial  model (Guagliardo,  2004).  These two aspects  – the
availability and accessibility  of  health care  –  were considered in
the model when we included the sample colection points and mea-
sured the accessibility by using the road network.
Two diferent network analysis methods were used when mod-
eling the least-cost therapy option. First, we applied Service Area
Analysis (ESRI,  2018a) to assess the least-cost  market areas for
both anticoagulation therapies (Figure 2). For inputs, we used the
maximum travel costs of an INR monitoring visit, calculated earli-
er using Eqs. 1a-1d for diferent monitoring scenarios. Travel costs
of travel modes in the road network were set separately using Eqs.
2a-2d in these analyses.  After each  Service  Area  Analysis, the
Origin-Destination Cost Matrix (ESRI, 2018b) method was used to
solve the travel distance from a sample colection point to the cut-
of isocost line of the market areas (Figure 2). These cut-of dis-
tances were calculated by utilising the output of the Service Area
Analysis, the locations of the sample colection points and the road
network.
Sensitivity analyses
We  performed sensitivity analyses for the annual cost  of
DOAC drugs. The cost of the DOACs was reduced by 25% from
the annual cost of our research period, folowing the assumption
that the  drug costs  would  decrease after  DOACs  become  more
commonly used and generic drugs are introduced. Other parame-
ters  were left  untouched  when applying the sensitivity analyses.
Sensitivity analyses were also performed to investigate the func-
tionality and stability of the model when input data changed. 
Results
The cut-of  distances  of the  market areas are  presented in
Figure  3.  These cut-of  distances  varied  between  0 and  58  km
when an INR monitoring frequency of 6 to 30 was considered by
travel modes in the model. The cut-of distances were based on the
prices of rivaroxaban or edoxaban in DOAC therapy. When com-
paring the cost-eficiency of warfarin therapy with DOAC therapy
with dabigatran and apixaban, the cut-of distances were slightly
longer in al cases due to the lower retail price of these DOACs.
The results show that the widest least-cost market area for war-
farin therapy was achieved by private car. For example, the cut-of
distance for warfarin therapy with 12 annual INR monitoring visits
was 15.5 km for a working person and 23.0 km for a retiree. With
higher INR monitoring frequencies, private car was stil the most
cost-eficient travel mode, but the cut-of distances shrank slowly
when the frequency increased.
The  model  would  produce even longer cut-of  distances for
public transport, but the size of the available public transport net-
work limits the range of usage to the suroundings of the city of
Joensuu. However, the cut-of distance decreased rapidly when the
INR monitoring frequency increased, leading to the situation that
traveling by public transport is not afordable for working persons
on warfarin therapy (if freq≥19) and retirees (if freq>30), not even
for short  distances. In this case,  DOAC therapy emerges as the
least-cost option, regardless of travel distance and domicile loca-
tion (Figure 3). By walking, warfarin therapy is the least-cost ther-
apy option for patients living in the relatively large areas around
sample colection  points,  but the  value  of time  has a substantial
impact on the extent of these areas between working persons and
retirees. Walking to INR monitoring was found to be cost-eficient
from 3.6 km for a working person, even unrealisticaly up to 11.8
km for a retiree due to afordability of walking when the number
of annual folow-up visits was 12 (Figure 3).
The smalest least-cost  market area for  warfarin therapy is
reached when taxi is used as it is the most expensive travel mode
in the model. The maximum cost-eficient traveling distance for a
one-way trip by taxi was 2.0 km for a working person and 3.5 km
for a retiree when the number of annual folow-up visits was 12.
Due to high direct monetary travel costs, taxi is not a cost-eficient
travel mode for frequent traveling at any distance for working per-
sons on warfarin therapy (if freq≥17) and retirees (if freq≥21).
The  market areas  of the therapies for a  working  person are
visualised in Figure 4. Private car, taxi, walking and public trans-
port were al feasible travel modes with regard to warfarin therapy
when a working person does not live far from the sample colection
point and the frequency of folow-up visits folows the normal care
guidelines. DOAC therapy was mostly the least-cost option in rural
areas, but the frequent use of taxi or public transport for warfarin
therapy  makes  DOAC therapy the least-cost  option also in some
urban areas for working persons.
Figure  5  presents the  market areas  of therapies for a retiree
when the patient has the recommended number of INR monitoring
visits. Warfarin therapy seems to be the least-cost option for every
travel  mode in the  most  populated areas  when the annual INR
monitoring frequency is simulated  by  10,  14 and  18  visits.  The
widest market area was reached by private car (freq=10), and this
area covers almost the  whole study region  with exception  of the
most outlying rural areas (Figure 5). Only the combination of taxi
and  warfarin therapy  was  partly limited in  urban areas from the
least-cost point of view for retirees. 
Sensitivity analysis shows  how the  DOAC  price reduction
expands the market area of DOAC therapy as the least-cost therapy
(Figure 3). The efect of price reduction was strongly cuting taxi
rides and  public transport  when  warfarin is  used. If the  price  of
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DOAC can be reduced by 25%, DOAC therapy wil become the
least-cost option everywhere for a working person using a taxi for
more than  12  visits  or  public transport for  more than  14  visits
annualy.  Moreover, after the  price reduction, the  market area  of
warfarin therapy for a working person was limited to a smal area
by walking. For a retiree, the warfarin therapy combined with trav-
eling by taxi was the least-cost option only if the patient requires
less than 16 annual visits; even then, only from the close vicinity
of a sample colection  point.  The influence  of the  DOAC  price
reduction would also have an efect on the patients who travel by
private car, shifting the borderline of the least-cost market area of
warfarin therapy closer to urban areas.
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Figure 3. The cut-of distances of therapy market areas for a working person and a retiree by travel modes. The figure contains theresults for both direct oral anticoagulant (DOAC) price classes and the outcome of sensitivity analyses. The area below the curve showsthe  distances and international  normalized ratio  monitoring frequency  when  warfarin therapy including traveling is the least-costoption for a patient, and the area above the curve shows the respective values when DOAC therapy becomes the least-cost option.
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Figure 4. The least-cost market areas of anticoagulation therapies for a working person. 10, 14 and 18 annual international normalizedratio (INR) monitoring visits were used as inputs. Three classes of market areas (grey shades) show warfarin therapy. Direct oral anti-coagulant therapy is more afordable for patients in the areas outside each particular class.
Figure 5. The least-cost market areas of anticoagulation therapies for a retiree. 10, 14 and 18 annual international normalized ratio(INR) monitoring visits were used as inputs. Three classes of market areas (grey shades) show warfarin therapy. Direct oral anticoagu-lant therapy is more afordable for patients in the areas outside each particular class.
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Discussion and Conclusions
The aim of the study was to create a general geospatial model
that can be used to determine the optimal alocation of anticoagu-
lation therapies for  diferent  geographical areas from the  AF
patients’  perspective.  The  model  was tested in the area  of  North
Karelia, and the outputs of the model can be reliably applied in the
Finnish context and should be tested also in other areas. 
Our results show that in both age groups, warfarin therapy is
the least-cost option in the close vicinity of the sample colection
points with al four travel modes when the patients do not require
more than the recommended number of INR monitoring visits. By
private car,  warfarin therapy is also the least-cost  option in the
majority  of rural areas.  Respectively,  DOAC therapy is spatialy
the least-cost option for AF patients who live farther away from the
INR sample colection  points,  or  whose annual INR  monitoring
frequency is high despite the location of the domicile. Both the fre-
quency of INR monitoring visits and the travel mode used in war-
farin therapy substantialy afect the size of the least-cost market
areas  of anticoagulation therapies. Additionaly, the  valuation  of
time causes remarkable diferences in the spatial costs of therapies
between working persons and retirees. 
In the sensitivity analyses,  we simulated a reduction  of the
annual DOAC prices to investigate how it would influence on the
extents of the market areas of warfarin and DOAC therapies. The
size of least-cost market areas for DOAC therapy increases when
the drug price fals. The price reduction of 25% leads to a situation
where regular traveling to INR monitoring by taxi or public trans-
port in no more the optimal option for a working person anywhere,
as DOAC therapy becomes cheaper. For a retiree, warfarin therapy
is stil the least-cost option in most cases near the sample colection
points, although the  distance  must  be short  by taxi.  The  model
showed its faultless appropriateness in sensitive analyses and al
stages of model runs and in diferent INR monitoring scenarios. 
Marcolino et al. (2016) described potential patient profiles for
whom the shift from warfarin to DOAC therapy could be econom-
icaly atractive in  Brazil.  The results from this study show that
DOAC therapy would be appropriate among non-elderly patients
due to the higher costs of TL, and among patients living at least 20
km away from a sample colection  point,  because transportation
causes  more significant travel costs.  Both  patient  profiles  of
DOAC users match our results, but in some cases, our model pro-
duced even shorter distances due to the lower out-of-pocket drug
costs in our study area.
Patient costs are dificult to compare due to the completely dif-
ferent execution  of these two anticoagulation therapies.  To
improve the knowledge of the spatial cost-eficiency of the antico-
agulation therapies, we ofer a new computational method to the
spatial targeting  of the least-cost anticoagulation therapy.  Earlier
studies have mostly compared the costs of therapies from the per-
spective of service costs (Verhoef et al., 2012; Coyle et al., 2013;
Salata et al., 2016). Our model demonstrates the selection of the
least-cost option of anticoagulation therapies from the patient per-
spective. Both physicians and patients can utilise the new informa-
tion of the least-cost therapy option, which might increase the use
of DOACs for patients living farther away from sample colection
points and among those with a high frequency of INR monitoring
visits.  Moreover, the increase in the  use  of  DOACs can lead to
improvements in the quality of care, as DOACs have been shown
to decrease the rate of strokes and other complications more efi-
ciently (Verhoef et al., 2014).
In the study area, the availability of a public transport network
is mainly limited to the town of Joensuu, and the bus routes cover
only the  most  populated areas  with  variable service frequency.
Thus, the calculations of realistic spatial costs for public transport
is chalenging. The cost was determined by using the digital road
network with constant fare parameter for the public transport. In
the areas of higher public transport density than in this study area,
to achieve spatialy more accurate results of the travel costs with
respect to the therapies  used,  more comprehensive accessibility
calculation  methods, such as  multimodal accessibility  measure-
ments with temporal aspects, should be applied for public transport
journeys (Tenkanen et al., 2016). 
A potential source of uncertainty is the assumption that every
taxi ride  had to  be  organised individualy for each  patient.  The
Social Insurance Institution  of  Finland (2019)  has started to  use
taxi ridesharing, and part of the reimbursable journeys are organ-
ised this way. The modeled cut-of distances are accurate when a
patient pays the ful price of the journey and reimbursement of the
health care related travel cost has been considered. When patients
share the cost  of a taxi journey, it reduces the  monetary travel
costs. On the other hand, sharing a journey might increase the total
time  of an INR  monitoring  visit, and thus the cost,  which could
lead to even higher travel costs.
Our geospatial model can be developed and expanded to suit
diferent geographical areas. By changing the main cost parame-
ters and applying the local digital road network, the model can be
used without any need for modifications. It can also be utilised to
determine for the least-cost  options  of  diferent  drugs and treat-
ment processes, which can be done, either from the patient’s or the
health care sector’s point of view. However, the maximum limit of
time spent traveling should  be taken account if the  model is
applied at the individual level. The cost related to potential compli-
cations of warfarin and DOAC therapy was not considered in the
geospatial model, but this amendment can be added to the model
when the  outcomes  of  AF  patients  have  been folowed long
enough. Additionaly, the model can be developed to utilise elec-
tronic patient register data, after which the least-cost anticoagula-
tion therapies can be calculated for AF patients individualy. 
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